BACKGROUND AND AIMS: Despite the use of administrative data to perform epidemiological and cost-effectiveness research on patients with hepatitis B or C virus (HBV, HCV), there are no data outside of the Veterans Health Administration validating whether International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes can accurately identify cirrhotic patients with HBV or HCV. The validation of such algorithms is necessary for future epidemiological studies. METHODS: We evaluated the positive predictive value (PPV) of ICD-9-CM codes for identifying chronic HBV or HCV among cirrhotic patients within the University of Pennsylvania Health System, a large network that includes a tertiary care referral center, a community-based hospital, and multiple outpatient practices across southeastern Pennsylvania and southern New Jersey. We reviewed a random sample of 200 cirrhotic patients with ICD-9-CM codes for HCV and 150 cirrhotic patients with ICD-9-CM codes for HBV. RESULTS: The PPV of 1 inpatient or 2 outpatient HCV codes was 88.0% (168/191, 95% CI: 82.5-92.2%), while the PPV of 1 inpatient or 2 outpatient HBV codes was 81.3% (113/139, 95% CI: 73.8-87.4%). Several variations of the primary coding algorithm were evaluated to determine if different combinations of inpatient and/or outpatient ICD-9-CM codes could increase the PPV of the coding algorithm. CONCLUSIONS: ICD-9-CM codes can identify chronic HBV or HCV in cirrhotic patients with a high PPV and can be used in future epidemiologic studies to examine disease burden and the proper allocation of resources.
BACKGROUND AND AIMS: Despite the use of administrative data to perform epidemiological and cost-effectiveness research on patients with hepatitis B or C virus (HBV, HCV), there are no data outside of the Veterans Health Administration validating whether International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes can accurately identify cirrhotic patients with HBV or HCV. The validation of such algorithms is necessary for future epidemiological studies. METHODS: We evaluated the positive predictive value (PPV) of ICD-9-CM codes for identifying chronic HBV or HCV among cirrhotic patients within the University of Pennsylvania Health System, a large network that includes a tertiary care referral center, a community-based hospital, and multiple outpatient practices across southeastern Pennsylvania and southern New Jersey. We reviewed a random sample of 200 cirrhotic patients with ICD-9-CM codes for HCV and 150 cirrhotic patients with ICD-9-CM codes for HBV. RESULTS: The PPV of 1 inpatient or 2 outpatientHCV codes was 88.0% (168/191, 95% CI: 82.5-92.2%), while the PPV of 1 inpatient or 2 outpatientHBV codes was 81.3% (113/139, 95% CI: 73.8-87.4%). Several variations of the primary coding algorithm were evaluated to determine if different combinations of inpatient and/or outpatient ICD-9-CM codes could increase the PPV of the coding algorithm. CONCLUSIONS: ICD-9-CM codes can identify chronic HBV or HCV in cirrhotic patients with a high PPV and can be used in future epidemiologic studies to examine disease burden and the proper allocation of resources.
Authors: Vincent Lo Re; Jessica Volk; Craig W Newcomb; Yu-Xiao Yang; Cristin P Freeman; Sean Hennessy; Jay R Kostman; Pablo Tebas; Mary B Leonard; A Russell Localio Journal: Hepatology Date: 2012-10-14 Impact factor: 17.425
Authors: Mark D Boldt; Joel V Brill; Gary L Davis; Stuart C Gordon; Arthur Y Kim; Lawrence R Kosinski; Arnold G Levy; Ronald G Nahass; John I Allen Journal: Gastroenterology Date: 2013-11 Impact factor: 22.682
Authors: Stuart C Gordon; Paul J Pockros; Norah A Terrault; Robert S Hoop; Ami Buikema; David Nerenz; Fayez M Hamzeh Journal: Hepatology Date: 2012-10-09 Impact factor: 17.425
Authors: Robert P Myers; Puneeta Tandon; Michael Ney; Glenda Meeberg; Peter Faris; Abdel Aziz M Shaheen; Alexander I Aspinall; Kelly W Burak Journal: Liver Int Date: 2013-11-20 Impact factor: 5.828
Authors: Mahendra S Nehra; Ying Ma; Christopher Clark; Ruben Amarasingham; Don C Rockey; Amit G Singal Journal: J Clin Gastroenterol Date: 2013 May-Jun Impact factor: 3.062
Authors: Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: S C Gordon; F M Hamzeh; P J Pockros; R S Hoop; A R Buikema; E J Korner; N A Terrault Journal: Aliment Pharmacol Ther Date: 2013-08-25 Impact factor: 8.171
Authors: Dana D Byrne; Craig W Newcomb; Dena M Carbonari; Melissa S Nezamzadeh; Kimberly B F Leidl; Maximilian Herlim; Yu-Xiao Yang; Sean Hennessy; Jay R Kostman; Mary B Leonard; Russell Localio; Vincent Lo Re Journal: Ann Epidemiol Date: 2014-03-05 Impact factor: 3.797
Authors: Siddharth A Mahure; Joseph A Bosco; James D Slover; Jonathan Vigdorchik; Richard Iorio; Ran Schwarzkopf Journal: Clin Orthop Relat Res Date: 2018-02 Impact factor: 4.176
Authors: Xinyi Jiang; Hyun Jin Song; Wei Wang; Linda Henry; Lindsey M Childs-Kean; Vincent Lo Re; Haesuk Park Journal: J Manag Care Spec Pharm Date: 2021-07
Authors: Jason W Wen; Michael A Kohn; Robert Wong; Ma Somsouk; Mandana Khalili; Jacquelyn Maher; Michele M Tana Journal: Am J Gastroenterol Date: 2018-01-30 Impact factor: 10.864
Authors: James S Floyd; Marc Blondon; Kathryn P Moore; Edward J Boyko; Nicholas L Smith Journal: Pharmacoepidemiol Drug Saf Date: 2015-11-11 Impact factor: 2.890
Authors: Danielle R Fine; Liyang Yu; Virginia A Triant; Travis P Baggett; Joshua P Metlay Journal: J Gen Intern Med Date: 2020-03-23 Impact factor: 5.128